

3 November 2016

Release of the 2016/17 Invitation to Tender

The 2016/17 Invitation to Tender (2016/17 ITT) has been distributed today.

If you have already registered your e-mail address with PHARMAC's new tendering e-portal you can access the 2016/17 ITT in the e-portal in Current Tenders.

If you have not registered your company with the e-Portal, and you would like to participate in the 2016/17 ITT, please register at <https://in-tendhost.co.uk/pharmac/asp/Home>.

A complete copy of the 2016/17 ITT is available on our website at the following link <http://www.pharmac.health.nz/news/#tender>. We will not be posting out any hard copies of the 2016/17 ITT.

1. Changes to the 2016/17 ITT product list

Please note that the product list (Schedule Two) consulted on in August 2016 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (i.e. from the Tender Medical Evaluation Subcommittee of PTAC and/or members of the Hospital Pharmaceuticals Subcommittee); and/or
- consultation responses received from suppliers, DHBs and/or medical groups; and/or
- a review of unresolved bids from previous tenders; and/or
- Alternative Commercial Proposals accepted by PHARMAC.

The following items have been added to the 2016/17 ITT:

Chemical Name	Line Item
Alfacalcidol	Cap 0.25 mcg
Alfacalcidol	Cap 1 mcg
Alfacalcidol	Oral drops 2 mcg per ml
Amorolfine	Nail soln 5%
Anastrozole	Tab 1 mg
Beclomethasone Dipropionate	Metered aqueous nasal spray, 50 mcg per dose
Benzylpenicillin Sodium [Penicillin G]	Inj 3 g
Brinzolamide	Eye drops 1%
Budesonide	Metered aqueous nasal spray, 50 mcg per dose
Budesonide	Metered aqueous nasal spray, 100 mcg per dose
Bumetanide	Tab 1 mg
Calcipotriol	Crm 50 mcg per g

Chemical Name	Line Item
Calcipotriol	Oint 50 mcg per g
Calcipotriol	Soln 50 mcg per ml (pack size 30 ml or greater)
Colestimethate	Inj 150 mg
Darunavir	Tab 400 mg
Darunavir	Tab 600 mg
Ephedrine	Inj 3 mg per ml, 10 ml prefilled syringe
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets
Flucloxacillin Sodium	Inj 2 g
Granisetron	Inj 1 mg per ml

Chemical Name	Line Item
Hyoscine N-butylbromide	Inj 20 mg, 1 ml
Hyoscine N-butylbromide	Tab 10 mg
Levetiracetam	Oral liq 100 mg per ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 5 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 20 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 5 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 20 ml
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg
Lopinavir with ritonavir	Oral liq 80 mg with ritonavir 20 mg per ml
Lopinavir with ritonavir	Tab 200 mg with ritonavir 50 mg
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg (electrolyte free)
Mercaptopurine	Tab 10 mg
Mercaptopurine	Tab 50 mg
Methylphenidate Hydrochloride	Tab immediate-release 5 mg
Methylphenidate Hydrochloride	Tab immediate-release 20 mg
Methylphenidate Hydrochloride	Tab immediate-release 10 mg

Chemical Name	Line Item
Methylphenidate Hydrochloride	Tab sustained-release 20 mg
Moxifloxacin	Tab 400 mg
Nitrofurantoin	Tab modified-release 100 mg
Nitrofurantoin	Tab 50 mg
Nitrofurantoin	Tab 100 mg
Orphenadrine Citrate	Tab 100 mg
Paracetamol (split market)	Tab 500 mg (blister; any pack size)
Paracetamol (split market)	Tab 500 mg (bottle; pack size of 500 or more)
Tamoxifen citrate	Tab 10 mg
Tamoxifen citrate	Tab 20 mg
Testosterone	Transdermal patch 5 mg
Tetracaine [amethocaine] hydrochloride	Gel 4%
Travoprost	Eye drops 0.004%
Tretinoin	Crm 0.5 mg per g
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Oral liq trimethoprim and sulphamethoxazole
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Tab trimethoprim 160 mg and sulphamethoxazole 800 mg
Zinc and castor Oil	Oint 5% or less (pack size 30 g or less)
Zinc and castor Oil	Oint 5% or less (pack size greater than 30 g)
Zinc and castor Oil	Oint BP (pack size greater than 30 g)

The following items that were included in consultation have been removed from the 2016/17 ITT:

Chemical Name	Line Item
Abacavir sulphate	Oral liq 20 mg per ml
Abacavir sulphate	Tab 300 mg
Atazanavir Sulphate	Cap 150 mg
Atazanavir Sulphate	Cap 200 mg

Chemical Name	Line Item
Benzoyl peroxide	Soln 5%
Brimonidine Tartrate with Timolol Maleate	Eye drops 0.2% with timolol maleate 0.5%
Paraffin (current access)	White soft - 2,500 g

Chemical Name	Line Item
Paraffin (widened access)	White soft - 2,500 g

The following items have been amended in the 2016/17 ITT:

Chemical Name	Line Item
Acitretin	Cap 10 mg
Acitretin	Cap 25 mg
Allopurinol	Tab 100 mg
Allopurinol	Tab 300 mg
Amikacin	Inj
Artemether with lumefantrine	Tab 20 mg with lumefantrine 120 mg
Atovaquone with proguanil hydrochloride	Tab 250 mg with proguanil hydrochloride 100 mg
Atovaquone with proguanil hydrochloride	Tab 62.5mg with proguanil hydrochloride 25 mg (Paediatric)
Carmellose sodium with gelatin and pectin	Paste
Cetrimide	Solution 20% (pack size of 100 ml or less)
Clarithromycin	Tab 500 mg
Dexmedetomidine hydrochloride	Inj 100 mcg per ml, 2 ml vial
Diazepam	Tab 2 mg
Escitalopram	Tab 10 mg
Glucose [Dextrose]	Inj 50%, 10 ml - 20 ml
Glucose [Dextrose]	Inj 50%, 90 ml - 100 ml
Haloperidol decanoate	Inj 100 mg per ml, 1 ml ampoule
Haloperidol decanoate	Inj 50 mg per ml, 1 ml ampoule
Hydrocortisone Butyrate	Oint 0.1% (pack size of 100 g or less)
Isotretinoin	Cap 5 mg
Ketoconazole	Shampoo 2%
Levodopa with Carbidopa	Tab 100 mg with carbidopa 25 mg
Levodopa with Carbidopa	Tab 250 mg with carbidopa 25 mg
Levodopa with Carbidopa	Tab long-acting 200 mg with carbidopa 50 mg
Levomepromazine	Tab 100 mg
Levomepromazine	Tab 25 mg

Chemical Name	Line Item
Levonorgestrel	Subdermal implant
Lidocaine [lignocaine] hydrochloride	Oral [viscous solution/gel] 2%
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg
Morphine sulphate	Tab immediate-release 10 mg
Morphine sulphate	Tab immediate-release 20 mg
Pancuronium bromide	Inj 2 mg per ml, 2 ml
Paracetamol	Tab 500 mg (pack size of 100 or less)
Paracetamol	Tab soluble 500 mg
Paracetamol (combined market)	Tab 500 mg
Paraffin (widened access)	White soft - 500 g
Pegylated interferon alpha-2a	Inj 135 mcg
Pegylated interferon alpha-2a	Inj 135 mcg with ribavirin
Pegylated interferon alpha-2a	Inj 180 mcg
Pegylated interferon alpha-2a	Inj 180 mcg with ribavirin
Pegylated interferon alpha-2b with ribavirin	Inj 100 mcg with ribavirin
Pegylated interferon alpha-2b with ribavirin	Inj 120 mcg with ribavirin
Pegylated interferon alpha-2b with ribavirin	Inj 150 mcg with ribavirin
Pegylated interferon	Inj 50 mcg with ribavirin

Chemical Name	Line Item
alpha-2b with ribavirin	
Pegylated interferon alpha-2b with ribavirin	Inj 80 mcg with ribavirin
Primaquine phosphate	Tab 7.5 - 15 mg
Pyrazinamide	Tab 500 mg
Pyrimethamine	Tab 25 mg
Ranitidine	Inj 10 mg - 25 mg per ml
Ribavirin	Tab 600 mg
Rifampicin	Tab 600 mg
Silver Sulphadiazine	Crn 1% (pack size of 100 g or less)
Sodium nitroprusside	Urinary Ketone Test Strip
Testosterone	Transdermal patch 2.5 mg
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg

Appropriate pack-size and packaging type

Where possible, PHARMAC has identified Tender Items where there is a specific preference for a pack size or packaging type in Schedule Two of the 2016/17 ITT document. For example (highlighted in red):

SCHEDULE TWO: PRODUCTS TO BE TENDERED						
Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Allopurinol						
<u>Tab 100 mg</u>	18,654,466	\$296,606	\$0.0159	C H 1%	A scored tablet is preferred	
<u>Tab 300 mg</u>	12,764,511	\$427,611	\$0.0335	C H 1%	A scored tablet is preferred	
Amantadine hydrochloride						
<u>Cap 100 mg</u>	674,910	\$430,143	\$0.6373	C H 1%		
Amikacin						
Inj 15 mg per ml, 5 ml				H 1%	Preference for syringes	

While PHARMAC has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

Oncology injectables

DHBs are increasingly delivering chemotherapy treatment in satellite centers which require compounded products to have a shelf-life greater than 24 hours to account for delays in treatment transport and delivery. Due to this PHARMAC has indicated a preference for products where stability data post-compounding is greater than 48 hours in Schedule Two of the 2016/17 ITT document (highlighted in red).

<p>Cyclophosphamide Inj 1 g</p> <p>Inj 2 g</p>	<p>H PCT 1%</p> <p>H PCT 1%</p>	<p>Preference for products where stability data >48 hours post-compounding</p> <p>Preference for products where stability data >48 hours post-compounding</p>
---	------------------------------------	--

Ophthalmology Products (BAK-free)

For a number of Ophthalmology products, as indicated in Schedule Two of the 2016/17 ITT document, PHARMAC reserves its right to list a benzalkonium chloride (BAK) or preservative-free product for a restricted market. However, where a tender product is BAK-free it would have the entire market.

Data estimates for PCT injectable products included in the 2016/17 ITT

PHARMAC makes no representation as to the accuracy of this information or as to the level of sales or likely sales and, while PHARMAC has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

In order to be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2016/17 ITT remains open.

Usage data for PCT injectable products

Chemical	Total usage ^{1,2,3}
Calcium folinate	3,047,600
Docetaxel	499,500
Gemcitabine hydrochloride	10,583,300
Methotrexate	5,668,155
Paclitaxel	1,588,400

¹Usage in mg, for period between 1 January 2015 to 31 December 2015

²All CPB usage data is included, which includes PCT hospital claims and non-PCT community pharmacy usage (e.g. community pharmacy dispensing).

³All CPB injectable (non-prefilled) and ECP usage data only.

These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item.

Data estimates for hospital usage

Hospital usage for the products included in the 2016/17 annual tender has been provided as an attachment to the 2016/17 Invitation to Tender. The units provided in the hospital usage data are for the hospital market only. Unit volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these unit volumes or to the level of sales or likely sales of any tender item. PHARMAC accepts no liability for any errors or omissions in this information.

Clarification of widening of access for paraffin 500 g

PHARMAC would only award a tender for either current access or widened access for the tender for paraffin 500 g. Widening of access would be for removal of 'only in combination' restriction.

Clarification of widening of access for ciprofloxacin eye drops 0.3%

PHARMAC would only award a tender for either current access or widened access for the tender for ciprofloxacin eye drops 0.3%. Widening of access would be for amendment of the wording 'are only funded for use in the eye, unless explicitly stated otherwise' to 'are funded for second line treatment of bacterial infections'.

2. Amendments to the provisions in the 2016/17 Invitation to Tender

Matters for evaluation

PHARMAC have included a provision in the 2016/17 Invitation to Tender relating to matters for evaluation.

The Evaluation Committee will evaluate Tender Bids in light of PHARMAC's statutory objective which is "to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided". In doing so the Evaluation Committee will be guided by the Factors for Consideration (Factors) that form part of PHARMAC's then current Operating Policies and Procedures (OPPs), as published on PHARMAC's website (www.pharmac.govt.nz), to the extent applicable. [More information on the Factors can be found on PHARMAC's website.](#)

The requirement for PHARMAC to pursue its statutory objective means that particular emphasis will be given to those aspects of proposals which demonstrate "health outcomes", and those aspects of proposals which demonstrate the impact on the "funding provided" for pharmaceuticals. Those Factors which relate directly to these aspects will be given the greatest weight by the Evaluation Committee but all Factors are important.

PHARMAC pack size preferences

PHARMAC have included a provision in the 2016/17 Invitation to Tender relating to pack size preference.

In summary, where a Tender Item is specified as being available for a Tender Bid for Sole Supply Status, it is the preference of PHARMAC that the pack size for such a Tender Item is a 30 or 90 day pack where the Tender Item is in a tablet or capsule form.

Notwithstanding the preference of PHARMAC for Tender Items to be in pack sizes as specified above, pack sizes may be specified in the comments column in the attached list or you may submit, and PHARMAC will consider and may accept, a Tender Bid for any pack size, including larger pack sizes, following its evaluation of Tender Bids under clause 5 of Schedule Three.

Product identification codes

Following consultation, PHARMAC are not amending the provision in the 2016/17 Invitation to Tender relating to product identification codes.

More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts at tender@pharmac.govt.nz.